Zyversa Therapeutics, Inc.盘中异动快速上涨8.16%报5.30美元_老虎社区_美港股上老虎

Zyversa Therapeutics, Inc.盘中异动快速上涨8.16%报5.30美元

自选股智能写手07-15

北京时间2024年07月15日21时32分，Zyversa Therapeutics, Inc.（ZVSA.us）股票出现异动，股价急速拉升8.16%。截至发稿，该股报5.30美元/股，成交量4846股，换手率0.58%，振幅2.45%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-2.83百万美元，每股收益-4.53美元，毛利-10439.00美元，市盈率-0.01倍。机构评级方面，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2451425628?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-15 21:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2451425628","market":"us","top_or_hot":-1,"title":"Zyversa Therapeutics, Inc.盘中异动 快速上涨8.16%报5.30美元","media":"自选股智能写手","content":"<div>\n<p>北京时间2024年07月15日21时32分，Zyversa Therapeutics, Inc.（ZVSA.us）股票出现异动，股价急速拉升8.16%。截至发稿，该股报5.30美元/股，成交量4846股，换手率0.58%，振幅2.45%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-2.83百万美元，每股收益-4.53美元，毛利-10439.00美元，市盈率-0.01倍。机构评级方面，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407152132099f4f231e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zyversa Therapeutics, Inc.盘中异动 快速上涨8.16%报5.30美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZyversa Therapeutics, Inc.盘中异动 快速上涨8.16%报5.30美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-15 21:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407152132099f4f231e&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2024年07月15日21时32分，Zyversa Therapeutics, Inc.（ZVSA.us）股票出现异动，股价急速拉升8.16%。截至发稿，该股报5.30美元/股，成交量4846股，换手率0.58%，振幅2.45%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-2.83百万美元，每股收益-4.53美元，毛利-10439.00美元，市盈率-0.01倍。机构评级方面，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407152132099f4f231e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407152132099f4f231e&s=b","article_id":"2451425628","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407152132099f4f231e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2451425628","pubTimestamp":1721050329,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2024年07月15日21时32分，Zyversa Therapeutics, Inc.股票出现异动，股价急速拉升8.16%。Zyversa Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。Zyversa Therapeutics, Inc.公司简介：ZyVersa Therapeutics Inc 是一家临床阶段的生物制药公司，利用专有技术为医疗需求未得到满足的慢性肾脏或炎症性疾病患者开发药物。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","ZVSA":"ZYVERSA THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Zyversa Therapeutics, Inc. jumped 8.16% to $5.30 in intraday moves","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ZVSA":0.9},"content_text":"北京时间2024年07月15日21时32分，Zyversa Therapeutics, Inc.（ZVSA.us）股票出现异动，股价急速拉升8.16%。截至发稿，该股报5.30美元/股，成交量4846股，换手率0.58%，振幅2.45%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-2.83百万美元，每股收益-4.53美元，毛利-10439.00美元，市盈率-0.01倍。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。Zyversa Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，Scinai Immunotherapeutics Ltd、Aeon Biopharma, Inc.、Humacyte Inc C/Wts 27/08/2026 (To Pur Com)涨幅较大，Scinai Immunotherapeutics Ltd、Artelo Biosciences, Inc.、Qualigen Therapeutics, Inc.较为活跃，换手率分别为990.94%、92.57%、47.26%，振幅较大的相关个股有Scinai Immunotherapeutics Ltd、Aeon Biopharma, Inc.、Humacyte Inc C/Wts 27/08/2026 (To Pur Com)，振幅分别为17.98%、13.93%、11.17%。Zyversa Therapeutics, Inc.公司简介：ZyVersa Therapeutics Inc 是一家临床阶段的生物制药公司，利用专有技术为医疗需求未得到满足的慢性肾脏或炎症性疾病患者开发药物。 该公司拥有两个专有的全球许可药物开发平台，即Cholesterol Efflux MediatorTM，VAR 200（2-羟丙基-β-环糊精）是一种处于临床开发阶段的用于治疗肾脏疾病的注射药物。 IC 100 是一种单克隆抗体炎性体 ASC 抑制剂，处于临床前开发阶段，用于治疗炎症。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}